Should You Buy GTBIF Stock After Marijuana Reclassification Order?

Core Insights - Shares of Green Thumb Industries (GTBIF) increased nearly 35% in the past month due to an executive order by President Trump to reschedule marijuana at the federal level [1][11] - The executive order directs federal agencies to expedite the reclassification of marijuana from Schedule I to Schedule III, acknowledging its medical value and representing a significant regulatory shift for the U.S. cannabis industry [3][6] - Rescheduling could improve long-term profitability for operators like Green Thumb by eliminating IRS Code 280E, which currently inflates effective tax rates [4][11] Regulatory Developments - The executive order marks a positive regulatory shift, although it does not provide a specific implementation timeline or address federal legalization of adult-use cannabis [6] - The reclassification may support broader medical research efforts and enhance the legitimacy of cannabis-based therapies, benefiting established operators with consumer packaged goods and medical portfolios [5] Financial Performance - Green Thumb's Q3 2025 revenues rose nearly 2% year over year to over $291 million, driven by strength in its CPG portfolio and contributions from new adult-use markets [9] - Comparable store sales declined 7% during the quarter due to pricing pressure and increased competition, while gross margin fell 200 basis points to 49.4% [10][11] - Despite these challenges, EPS (excluding one-time gains) remained flat year over year at 4 cents, indicating operational resilience [10] Competitive Landscape - Green Thumb operates in a highly competitive U.S. cannabis market, facing pricing pressures and competition from peers like Canopy Growth and Cresco Labs [13] - Unlike its competitors, Green Thumb is fully reliant on the U.S. market, which is fragmented and crowded, limiting its growth avenues compared to those expanding internationally [14] Future Outlook - The company is expected to remain under pressure due to persistent pricing compression in maturing markets, with management anticipating Q4 2025 revenues to be flat or up low single digits [12] - While marijuana reclassification is a significant policy milestone, it does not fundamentally change the near-term operating outlook for cannabis companies focused on adult-use markets [18] - Existing shareholders may maintain exposure in anticipation of long-term reform, but prospective investors are advised to wait for clearer evidence of sustainable earnings growth [19]